Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells.
Dalton Trans
; 50(27): 9500-9511, 2021 Jul 13.
Article
em En
| MEDLINE
| ID: mdl-34254615
ABSTRACT
Carbosilane ruthenium(ii) dendrimers have been complexed with conventional anti-cancer drugs. Due to its features, the presence of ruthenium within a dendrimer structure improves the anti-cancer properties of nanocomplexes containing 5-flurouracyl, methotrexate and doxorubicin. These dendrimers could be promising carriers of anti-cancer medicines. Ruthenium dendrimers that are positively charged can also enhance the cytotoxicity to cancer cells; moreover, they can form stable complexes with drugs. Results indicate that ruthenium dendrimers combined with doxorubicin and methotrexate significantly reduced the viability of leukaemia 1301 and HL-60 cancer cells.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rutênio
/
Silanos
/
Doxorrubicina
/
Metotrexato
/
Nanoestruturas
/
Dendrímeros
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Dalton Trans
Assunto da revista:
QUIMICA
Ano de publicação:
2021
Tipo de documento:
Article